Upgrade to SI Premium - Free Trial

Gilead (GILD) New Drug Filgotinib is Relatively Safe, But Black Box Still Likely - Baird

May 21, 2020 9:37 AM
Baird analyst Brian Skorney reiterated a Neutral rating and $75 price target on Gilead Sciences (NASDAQ: GILD) citing earnings stabilization ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles